Estimation of three-parameter Fréchet distribution for the number of days from drug administration to remission in small sample sizes

Author:

Ogura Toru1,Shiraishi Chihiro2

Affiliation:

1. Clinical Research Support Center, Mie University Hospital, Mie, Japan

2. Department of Pharmacy, Mie University Hospital, Mie, Japan

Abstract

In medical research, it is common to estimate parameters for each group and then evaluate the estimated parameters for each group without comparing the groups. However, researchers frequently want to determine whether the two distributions using the estimated parameters differ significantly between the two groups. For the Weibull distribution, the two-sample Kolmogorov-Smirnov test (two-sided) was used to examine whether the two distributions were significantly different between the two groups. Based on this, we developed a method to compare the two groups using a three-parameter Fréchet distribution. The number of days from drug administration to remission frequently followed a Fréchet distribution. It is appropriate to use a three-parameter Fréchet distribution with a location parameter because patients typically go into remission after several days of drug administration. We propose a minimum variance linear estimator with a hyperparameter (MVLE-H) method for estimating a three-parameter Fréchet distribution based on the MVLE-H method for estimating a three-parameter Weibull distribution. We verified the effectiveness of the MVLE-H method and the two-sample Kolmogorov-Smirnov test (two-sided) on the three-parameter Fréchet distribution using Monte Carlo simulations and numerical examples.

Publisher

IOS Press

Reference25 articles.

1. Bayesian analysis of three-parameter Frechet distribution with medical applications;Abbas;Computational and Mathematical Methods in Medicine,2019

2. Estimation of the unknown parameters of the generalized Frechet distribution;Abd-Elfattah;Journal of Applied Sciences Research,2009

3. Intravenous cyclophosphamide is the drug of choice for steroid dependent nephrotic syndrome;Bircan;Pediatrics International,2003

4. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis;Cattran;Kidney International Supplements,2012

5. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: A case series;Cortazar;BMC nephrology,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3